Celldex Therapeutics, Inc.
CLDX
$41.95
-$0.66-1.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -300.55M | -283.65M | -258.76M | -224.53M | -199.61M |
| Total Depreciation and Amortization | 3.40M | 3.37M | 3.38M | 3.38M | 3.35M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.42M | 31.22M | 30.37M | 28.77M | 26.27M |
| Change in Net Operating Assets | 31.16M | 26.90M | 14.06M | 12.90M | -16.20M |
| Cash from Operations | -235.57M | -222.16M | -210.95M | -179.48M | -186.19M |
| Capital Expenditure | -6.54M | -4.09M | -2.71M | -2.19M | -2.29M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -60.59M | 242.33M | 211.79M | 179.88M | 166.90M |
| Cash from Investing | -67.13M | 238.24M | 209.07M | 177.69M | 164.61M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 327.11M | 2.51M | 2.39M | 1.43M | 1.89M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 327.11M | 2.51M | 2.39M | 1.43M | 1.89M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.41M | 18.59M | 515.00K | -362.00K | -19.70M |